By Sharon Begley @sxbegle
Originally published July 21, 2016
Scientists in China plan to use the genome-editing technology CRISPR-Cas9 in patients as early as next month, Nature reported on Thursday. If they go ahead, it would be the first time people would be injected with cells whose DNA has been altered by CRISPR.
A US proposal to run a similar study received approval by a federal ethics and safety panel last month, but it faces months of additional regulatory hurdles before it can go ahead by the end of 2016 at the earliest. The Chinese scientists, led by oncologist Lu You of Sichuan University’s West China Hospital in Chengdu, received approval from the hospital’s review board on July 6, Nature reported, and plan to treat their first patient in August.
Both the US and Chinese scientists would use CRISPR to edit immune-system T cells in patients with cancer in an effort to make those cells destroy malignant cells.
The article is here.